Biomarker Testing and Targeting in NSCLC Equitable, Guideline-based Testing for Prognosis and Treatment

In the past decade, advances in non-small cell lung cancer (NSCLC) have rapidly evolved with the discovery of targetable mutations and subsequent therapies. However, suboptimal biomarker testing practices and varying adherence to testing guidelines presents a challenge to implementing targeted treatment. Are you ready to test your skills against those of your colleagues? Join us for Part 1 of this question and answer based educational activity Equitable, Guideline-based Testing for Prognosis and Treatment where our oncology experts will:  

• Review guideline recommendations for biomarker testing and treatment selection
• Present clinical evidence for the use of current and emerging targeted therapies
• Discuss health disparities in biomarker testing